Innovative research to tailor treatment dosing
Individualisation of treatment dosing adapts a treatment to a patients’ preferences and characteristics which, if successful, can make a therapeutic more effective. Learn how innovative new research can allow healthcare professionals to tailor natalizumab treatment to specific patients and their needs.
A large number of disease-modifying treatments are now available to treat MS patients and with each of these treatments there is a unique benefit risk balance to consider. Innovative new research is now allowing treatments to be tailored to individual patients. This is improving patient care by addressing specific patient situations and helping to meet the individual needs of patients.
Presented by Professor Sven Meuth, this section of the symposium answers the question: how can recent research be used to help tailor treatment dosing?
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Important background information
- Most Tysabri Observational Program (TOP) contributors are in Europe; hence these outcomes generally reflect the use of natalizumab as per the European label.
- This US-based observational study was performed in the US; hence the use of natalizumab as per the US label.
- Multiple Sclerosis Performance Test (MSPT): An ipad-based series of tests and questionnaires, including tests of cognitive processing cognitive processing speed, time to walk 25 feet and manual dexterity, where tests have been validated vs standard tests per Rao SM et al. Mult Scler. 2017;23(14):1929–1937; Rao SM et al. Eur J Neurol. 2020; 10.1111/ene.14162.